Clinical Trial Update: A Non-interventional Prospective Study of Early HER2-negative High-risk Breast Cancer and BRCA1/2 Mutations Prevalence in RussiA

View source ↗

Summary

A non-interventional prospective study conducted in Russia to assess the prevalence of BRCA1/2 mutations in early HER2-negative high-risk breast cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Snippet

Sponsor: AstraZeneca | Conditions: Breast Cancer | Status: ACTIVE_NOT_RECRUITING